Advisory: Alert from Equity-Insider.com was published in error and has been withdrawn
16/12/2025 17:43
An alert on cancer drug developers was inadvertently filed off a commentary by Equity-Insider.com and tagged to Immunome IMNM.O, Prelude Therapeutics PRLD.O, Context Therapeutics CNTX.O, Relay Therapeutics RLAY.O and Oncolytics ONCY.O. The alert has been withdrawn and there will be no substitute. STORY_NUMBER: nTUA1LWBBS STORY_DATE: 16/12/2025 STORY_TIME: 05:18:00 PM GMT ((bangalore.newsroom@thomsonreuters.com))
Recent news on Prelude Therapeutics Incorporated
See all newsBrief: Prelude Announces Clinical Trial Collaboration And Supply Agreement With Lilly To Evaluate KAT6A Selective Degrader PRT13722 In Combination With Verzenio® And Inluriyo® In Patients With HR+/HER2- Breast Cancer
U.S. RESEARCH ROUNDUP-Celcuity, Fluence Energy, Salesforce
Prelude Therapeutics Incorporated reports results for the quarter ended June 30 - Earnings Summary
Prelude Therapeutics Q2 revenue beats analyst expectations, net loss narrows
Prelude Therapeutics Incorporated expected to post a loss of 20 cents a share - Earnings Preview